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ABSTRACT We have constructed a PRCI-SUC2 gene
fusion that directs the synthesis in Saccharomyces cerevisiae of
a hybrid polypeptide consisting of a 433-residue amino-ter-
minal domain derived from the yeast vacuolar protease car-
boxypeptidase Y (CPY; EC 3.4.16.1) and a 511-residue
carboxyl-terminal domain derived from the secreted yeast
enzyme invertase (EC 3.2.1.26). Fractionation data indicated
that this amount of CPY primary sequence is sufficient to
quantitatively divert invertase to the yeast vacuole. The phe-
notypic consequence oflocalizing active invertase to the vacuole
has enabled us to select for mutants that "mislocalize" the
hybrid protein to the cell surface. The corresponding mutations
that lead to this effect are all trans-acting and recessive, and
they define at least eight complementation groups. These
vacuolar protein targeting (vpt) mutants also exhibit hybrid
protein independent defects in wild-type CPY delivery to the
yeast vacuole. Precursor forms of CPY accumulate in the
mutants and are secreted into the yeast periplasm and extra-
cellular medium. The vpt mutants should provide useful
information pertaining to the mechanisms by which yeast cells
regulate vacuolar protein traffic.
A property of all living cells is their ability to maintain a
proper level of biochemical compartmentalization. This or-
dered state is in large part achieved by cellular processes that
faithfully direct the efficient localization of defined subsets of
proteins from their cytoplasmic site of synthesis to their
various noncytoplasmic destinations. A major portion of
intracellular protein traffic in eukaryotes is mediated by the
secretory pathway. This pathway consists of a series of
membranous organelles that mediate the events associated
with the sorting, packaging, transport, and exocytosis of
glycoproteins. The basic structure of the yeast secretory
pathway has been elucidated and shown to be conserved with
respect to the secretory pathways of higher eukaryotes (1).
Furthermore, it has been demonstrated that yeast secretory,
plasma membrane, and vacuolar proteins transit at least
certain portions of the secretory pathway en route to their
ultimate subcellular compartments (2-4).
To better understand how the various classes of proteins
that transit the secretory pathway are sorted from each other,
we have undertaken an analysis of protein targeting to the
yeast vacuole. The yeast vacuole seems analogous to the
mammalian lysosome from the standpoint that a number of
glycoprotein hydrolases are sequestered within the organelle
(5). The intracellular passage of one such vacuolar enzyme,
carboxypeptidase Y (CPY; EC 3.4.16. 1), has been analyzed
in yeast cells that exhibit temperature-conditional defects at
various points in the secretory pathway (4). From these and
other studies it has been established that CPY is synthesized
as an inactive zymogen that is translocated into the lumen of
the endoplasmic reticulum, where it receives four N-
glycosidically linked core oligosaccharides (4, 6). Delivery to
the Golgi complex follows, and further glycosyl modifica-
tions of the pro-CPY take place in this organelle. Finally, the
pro-CPY is targeted to the vacuole, where an 8000-kDa
propeptide is removed to yield the active mature enzyme (7,
8). This maturation of CPY is dependent upon the presence
of a functional PEP4 gene product (8). The nature of the
information elaborated by pro-CPY that directs its localiza-
tion to the vacuole is not known. However, glycosylation
does not appear to play a role in the targeting process, as
unglycosylated CPY is still faithfully delivered to the yeast
vacuole (9).
To date, the available data suggest a common itinerary for
yeast secretory and vacuolar glycoproteins through the early
stages of the secretory pathway. These proteins are presum-
ably sorted and directed to their respective targets at the level
of the Golgi complex (1, 4). We have devised a gene
fusion-based selection for mutants that are defective in CPY
delivery to the yeast vacuole. These mutants mislocalize this
vacuolar hydrolase to the cell surface. In this report, we
describe the isolation and initial characterization of such
vacuolar protein targeting (vpt) mutants.
MATERIALS AND METHODS
Yeast Strains. Saccharomyces cerevisiae strains SEY2101
(MATa ura3-52 leu2-3,-112 suc2-A9 ade2-1) and SEY2102
(MATa ura3-52 leu2-3,-112 suc2-A9 his4-519) have been
described (10). Standard methods (11, 12) were employed to
construct yeast strains SEY2108 (MATa ura3-52 leu2-3,-112
suc2-A9 Aprcl::LEU2+), SEY2109 (MATa ura3-52 leu2-3,-
112 suc2-A9 Aprcl ::LEU2+), and SEY2101.1 (MATa ura3-52
leu2-3,-112 suc2-A9 ade2-1 Apep4::LEU2').
Media and Reagents. YPD and minimal yeast media have
been described (11). Minimal media were supplemented with
glucose (2%) and proline (1%) as sole carbon and nitrogen
sources, respectively. For sulfate-free media, chloride salts
were substituted for all sulfate salts. Bromcresol purple
indicator medium (11) was supplemented with sucrose (2%)
and antimycin A (10 ,ug/ml; Sigma). H235SO4 was obtained
from Amersham and lyticase was from Enzogenetics (Corval-
lis, OR). Tunicamycin and Ficoll 400-DL were purchased
from Sigma.
Transformation. Yeast were transformed to uracil-indepen-
dence with the appropriate plasmids by the lithium acetate
method (13).
Radiolabeling and Immunoprecipitation. Procedures for
radiolabeling yeast with 35SO2- in the presence or absence of
tunicamycin, cell fractionation, immunoprecipitation with
anti-CPY serum (gift of T. Stevens), and NaDodSO4/PAGE
have been described (14).
Abbreviations: CPY, carboxypeptidase Y; mCPY, mature CPY; Inv,
invertase.
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Fractionation. Yeast vacuoles were purified from cells
grown in glucose minimal proline medium. Yeast were
converted to spheroplasts in 0.2 M imidazole/0.6 M sorbitol
buffer (pH 6.5) with zymolyase as described by Daum et al.
(15). Spheroplasts were resuspended in 0.2 M sorbitol/0.2 M
imidazole/15% Ficoll/10 mg of bovine serum albumin per ml.
Lysis of spheroplasts was induced by addition of DEAE-
dextran to 30 Ag/100 OD6N units of cells (16). Vacuoles were
resolved on a discontinuous Ficoll step gradient (4) with the
one modification that an extra 4% Ficoll step was added.
Purified vacuoles were collected at the 4%/0% Ficoll inter-
face.
Conversion of yeast cells to spheroplasts with lyticase and
the collection of spheroplast and extracellular fractions has
been described (14).
Enzyme Assays. The assay procedures and unit definitions
for yeast invertase (17), a-mannosidase (18), a-glucosidase
(19), and NADPH-cytochrome c reductase (20) have been
described. Protein estimations were performed by the meth-
od of Lowry et al. (21).
RESULTS
Construction of the-PRC1-SUC2 Gene Fusion. The PRCO
gene of yeast encodes the vacuolar serine protease CPY (8).
PRCO has been cloned and its nucleotide sequence has been
determined (ref. 22; T. Stevens, personal communication).
SUC2 encodes the periplasmic glycoprotein invertase (EC
3.2.1.26; abbreviated Inv in fusion proteins). This gene also
has been cloned and its nucleotide sequence determined (23,
24). The coding sequence for a substantial amino-terminal
moiety (433 amino acids) of pro-CPY (532 amino acids) was
fused in-frame to a truncated form of the SUC2 gene, lacking
its 5' regulatory sequences and the coding sequence for its
amino-terminal signal peptide, to yield the pCYI433 shuttle
plasmid (Fig. 1A). When radiolabeling of yeast strain
SEY2101 (pCYI433) was performed in the presence of
tunicamycin, an inhibitor of core glycosylation, a CPY-
related polypeptide of some 105-110 kDa was precipitated
(Fig. 1B). The size of this protein was in very good agreement
with that expected (105-106 kDa) for the unglycosylated
CPY-Inv hybrid protein, as deduced from the nucleotide
sequence of the gene fusion. The apparent molecular mass of
this polypeptide was shifted to approximately 135-140 kDa
when the experiment was performed in the absence of
tunicamycin. Essentially identical results were observed
when invertase antiserum, rather than CPY antiserum, was
used for the immunoprecipitation (data not shown). We
interpreted these data to indicate that pCYI433 directed the
synthesis of a CPY-Inv hybrid protein of 105-110 kDa
apparent molecular mass that was core glycosylated at most,
if not all, of the 16 possible asparagine-linked glycosylation
sites. Each core glycosyl chain would be expected to increase
the apparent molecular mass of the fusion protein by 2-2.5
kDa. No difference in apparent hybrid protein molecular
mass was detected in PEP4+ relative to Apep4 yeast strains
(Fig. 1B), suggesting that the pro portion of the hybrid protein
was not processed.
OPY-Inv433 Is Targeted to the Yeast Vacuole. The CPY-
Inv433 hybrid protein exhibited invertase activity, which we
used as a marker to detect the cellular location of the hybrid
protein. When whole yeast cells are assayed for wild-type
invertase, essentially all of the activity is found to be secreted
to the yeast periplasm (ref. 25; data not shown). However,
quite different results were obtained with the invertase
activity elaborated by CPY-Inv433. When intact yeast were
assayed for external CPY-Inv activity, only some 2-5% of the
total invertase activity (260 units/OD6w unit of cells) was
measured at the cell surface. These values were comparable






















FIG. 1. (A) PRCI-SUC2 gene fusion. A 3.2-kilobase-pair
EcoRI-BglII DNA restriction fragment carrying the promoter and
coding sequence for the amino-terminal 433 amino acid residues of
the PRCI gene product was ligated into the SUC2 gene fusion vectors
pSEYC306 (CEN4-ARSJ URA3) and pSEY304 (2-,um circle URA3)
that had been digested with the restriction enzymes EcoRI and
BamHI. This generates an in-frame fusion between the PRCI and
SUC2 genes. The SUC2 fusion vectors pSEY304 and pSEYC306
contain the coding sequence for 511 amino acids of mature invertase.
These vectors lack the coding sequence for the 19-amino acid
invertase signal sequence and the first two amino acids of the mature
enzyme. (Construction of these vectors will be described elsewhere.)
The PRCO gene is divided into the coding regions for the presumed
signal peptide (filled-in box), the propeptide (hatched box), and the
mature CPY enzyme (stippled box). The approximate positions of the
asparagine-linked core oligosaccharides as determined from the
predicted amino acid sequences of the CPY and invertase proteins
are indicated above the PRCO and SUC2 genes. (B) Yeast strains
SEY2101 and SEY2101.1 (Apep4) harboring the PRCI-SUC2 gene
fusion were labeled for 20 min with 31SO42- in the presence and
absence of tunicamycin (10,g/ml). The cells were lysed with glass
beads prior to immunoprecipitation of the CPY-Inv hybrid protein
with anti-CPY serum. Precipitated proteins were subjected to
NaDodSO4/PAGE and autoradiography. The hybrid protein appears
to be susceptible to proteolytic cleavage or degradation that is not
dependent on PEP4 gene function.
surface for a-mannosidase, a vacuolar membrane marker
(18), and a-glucosidase, a cytoplasmic enzyme (19). Thus, the
amino-terminal 433 amino acids ofpro-CPY were sufficient to
redirect invertase to an intracellular compartment. The
fidelity of intracellular localization of CPY-Inv433 was a
function of gene dosage. Efficient intracellular compartmen-
talization of CPY-Inv433 required that the hybrid gene copy
number be low. In the case of yeast strains harboring
pCYI433, the gene fusion was present at 1-2 copies per cell.
When an 8- to 12-fold overproduction of CPY-Inv433 was
achieved by introducing the gene fusion into yeast on a
multicopy 2-gm circle plasmid vector (pSEY304), some
20-25% of the total invertase activity was secreted (data not
shown). In this respect, CPY-Inv433 mimicked the behavior
of wild-type CPY (22).
To determine whether the proCPY sequences present in
CPY-Inv433 were directing invertase to the yeast vacuole, we
isolated vacuoles from fusion-bearing yeast strains. Enzyme
markers for the vacuole membrane (a-mannosidase), the
70,-
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endoplasmic reticulum (NADPH-cytochrome c reductase),
and the cytoplasm (a-glucosidase) were assayed in crude cell
extracts and vacuole-enriched fractions. Total protein was
determined as well (Table 1). a-Mannosidase activity was
monitored to identify the vacuoles and to gauge vacuole
recovery during the fractionation (4, 18). Almost half (43%)
of the total a-mannosidase activity loaded onto the discon-
tinuous Ficoll gradient was recovered at the 4%/0%o Ficoll
interface after centrifugation. An essentially identical recov-
ery (41%) of the total invertase activity was also measured in
this vacuole fraction. Thus, a-mannosidase and CPY-Inv433
cofractionated. The purified vacuoles were substantially free
of contamination by endoplasmic reticulum and cytoplasmic
markers, and they represented an approximately 45- to
50-fold enrichment of vacuolar proteins with respect to total
cell protein applied to the gradient (Table 1). These data
indicated that CPY-Inv433 was targeted to the yeast vacuole.
Further evidence in support of the vacuolar localization of
CPY-Inv433 was obtained from indirect immunofluorescence
experiments (26) with invertase antibody that revealed vac-
uole fluorescence for strain SEY2108 (pCYI433) but not for
strain SEY2108 (data not shown).
Isolation of Mutants that Secrete CPY-1nv433. The efficient
delivery ofCPY-Inv433 to the yeast vacuole by strains having
no other source of invertase activity resulted in the inability
of such strains to grow on media with sucrose as their sole
fermentable carbon source. Presumably, the sucrose-nega-
tive phenotype reflected the inability of the cells to transport
sucrose into the yeast vacuole efficiently, thereby providing
a ready selection for mutants that mislocalize CPY-Inv433 to
the cell surface.
A total of 100 spontaneous sucrose-fermenting mutants
were isolated with strains SEY2101, SEY2102, SEY2108,
and SEY2109 bearing the pCYI433 plasmid. The selection
was performed in the presence of antimycin A, an inhibitor
of yeast respiratory metabolism (27). All but 2 of these
independently obtained mutants exhibited sucrose-ferment-
ing phenotypes that were recessive in heterozygous diploids.
All ofthe corresponding mutations were found to be unlinked
to the gene fusion. Complementation analyses identified at
least eight complementation groups which we have designat-
ed vptl-8 for vacuolar protein targeting (see below). Of the
98 recessive mutations analyzed, 57 were assigned to a
complementation group, with vptl being most commonly
represented, with 26 members.
To quantitate the 'level of CPY-Inv433 mislocalization to
the cell surface in the vpt mutants, we measured the relative
amounts of invertase activity that were secreted in a number
of the vpt mutants with respect to the low levels of exter-
nalized invertase measured in the isogenic VPT' parents.
Table 1. Subcellular localization of CPY-Inv433
Total Units % total
units recovered activity in
in crude in vacuole vacuole
Enzyme extract fraction fraction
a-Mannosidase 880 376 43
CPY-Inv433 17,000 7000 41
a-Glucosidase 2,230 10 0.4
NADPH-cyt c
reductase 763 21 2.7
Protein 3.6 mg 0.03 mg 0.9
Vacuoles were purified from SEY2108 pCPY-Inv433. Greater than
90%o of the total enzyme activities loaded onto the gradient were
recovered. a-Mannosidase, a-glucosidase, and NADPH-cyto-
chrome c reductase represented markers for yeast vacuole mem-
brane, cytoplasm, and endoplasmic reticulum, respectively. Enzyme
units were defined as nmol of substrate hydrolyzed per min.
Yeast strains were cultured in glucose minimal proline
medium and converted to whole cell, spheroplast, and
periplasmic fractions. The fractions were subsequently as-
sayed for the appropriate enzyme activities. Total activities
measured in the whole cell fractions were normalized to
100%, and the total enzyme activities measured for the
spheroplast and periplasmic fractions were expressed as
portions thereof. All of the vpt mutants tested exhibited a
dramatic mislocalization of invertase activity to the cell
surface. The parental SEY2108(pCYI433) strain exhibited
very little invertase, a-mannosidase, or a-glucosidase activ-
ity at the cell surface (see above). In contrast, the isogenic
vpt3-2, vpt4-2, and vpt6-2 strains secreted some 60%, 70%,
and 65% of the total cellular invertase activity, respectively.
In all cases, the recovery of the periplasmic and spheroplast
activities accounted for greater than 90% of the total enzyme
activities. It is important to note that a-mannosidase and
a-glucosidase activities (i) cofractionated with the vpt
spheroplasts, (ii) were not present in the periplasmic frac-
tions at significantly higher quantities than those measured
for the VPT+ strain, and (iii) the specific activities for
a-glucosidase and a-mannosidase in the vpt mutants were not
significantly different from those ofthe parental VPT+ strain.
Furthermore, we obtained recoveries of 25-35% of the
a-mannosidase activity with vacuoles purified from VPr,
vpt3-2, and vpt4-2 yeast, indicating that a-mannosidase
continues to cofractionate with the vpt mutant vacuoles.
These data indicated that the vpt mutants are selective in their
mechanisms of CPY-Inv433 secretion and are not unusually
prone to cell lysis or some other form of general leakiness.
The specific activity of invertase was the same in the isogenic
VPr and vpt strains, suggesting that the vpt mutants do not
overproduce CPY-Inv433 and secrete some fraction of the
hybrid molecule population by this mechanism.
vpt Mutants Accumulate Precursor Forms of CPY. If the vpt
mutants are defective in host functions that interact with
information elaborated by CPY sequences present in CPY-
Inv433, one might expect that these mutants would also
suffer defects in the proper localization of wild-type CPY. To
test this possibility, SEY2108 derivative strains were cured of
pCYI433 and made PRCJ + by transformation with the
CEN4-ARSI-based vector pCEN-PRC1. Normally, three
forms of CPY can be detected in wild-type yeast: the transit
intermediates pl and p2, and the mature vacuolar form
(mCPY). The pl species represents core glycosylated pro-
CPY (67 kDa) and is found at both the endoplasmic reticulum
and the Golgi complex (4). In the Golgi complex pl undergoes
further glycosyl modification to generate the 69-kDa p2 form.
Since PEP4-dependent conversion of p2 to mCPY is consid-
ered to occur in the vacuole (7, 8), we investigated the
kinetics of CPY maturation in VPT+ and vpt yeast as a first
approximation of the fidelity of CPY localization in the vpt
mutants (Fig. 2).
Previous studies of CPY delivery to the vacuole have
indicated a half-time for this process of some 6 min (7).
Kinetic analyses of CPY maturation in our VPIT strain are
consistent with that estimate (Fig. 2). The mature species was
stable throughout the entire 60-min chase period. Isogenic vpt
strains exhibited markedly different CPY profiles. All of the
vpt mutants represented in Fig. 2 were defective in CPY
maturation, and they accumulated predominantly the 69-kDa
(p2) precursor form. Reduced amounts of a CPY species that
was electrophoretically indistinguishable from mCPY were
also observed in these strains. The vptl-3 strain seemed to
generate the greatest fraction of mCPY. In kinetics experi-
ments where chase times of short duration (<20 min) were
analyzed, some 30% of the radiolabeled CPY antigen was
estimated to have been matured in this mutant. Other
mutants, such as the vpt3-2 and vpt7-2 strains, were estimated
to have converted as little as 10% of the recovered CPY to the
Genetics: Bankaitis et al.
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FIG. 2. Kinetics of CPY maturation in wild-type and vpt mutant
yeast. Cells grown in glucose minimal proline medium were labeled
with 35SO4- for 15 min. Chase was initiated by adding unlabeled
SO} to 10 mM and terminated at the indicated times (min) by adding
trichloroacetic acid to a final concentration of 5%. CPY was
immunoprecipitated and analyzed by NaDodSO4/PAGE and
autoradiography (4). The mature (mCPY) and p2 precursor (pCPY)
forms are indicated.
mature form. Mutants representative of vpt complementation
groups not included in the experiment shown in Fig. 2
exhibited defects in CPY maturation similar to those pre-
sented here (data not shown). The p2 CPY that accumulated
in the vpt mutants was unstable. This susceptibility to
degradation was a result of p2 CPY mislocalization to the cell
surface (see below). Since equivalent amounts of protein
were loaded on the NaDodSO4 gels in Fig. 2, the fractions of
mCPY observed at late chase points represents an overesti-
mation of the true amount of p2 CPY that was matured.
vpt Mutants Mislocalize CPY to the Periplasm and the
Culture Medium. Since the vpt mutants secreted a large
percentage of CPY-Inv433 to the yeast periplasm and ap-
peared to exhibit fusion-independent defects in CPY local-
ization, isogenic VPTS and vpt yeast were fractionated to
determine the ultimate fate of the mislocalized CPY (Fig. 3).
In these experiments, the whole culture (W) fractions served
as indicators of total quantities of CPY antigen. Note that in
the VPIT strain the great majority of labeled CPY recovered
from the W fraction was mCPY that fractionated with the
intact spheroplasts, a property consistent with the vacuolar
residence of this CPY form in wild-type yeast. Very little
CPY antigen was recovered from the periplasmic and culture
medium fractions. The mCPY observed in the periplasmic
fraction was probably due to a small amount (<5%) of
spheroplast lysis during the fractionation procedure. The
CPY detected in the culture medium, however, was exclu-
sively in the p2 form and its presence was not due to cell lysis.
Our evidence indicates that the VPT+ strain utilized in these
studies normally secretes trace quantities (2-5%) of p2 CPY
into the extracellular medium.
Fractionation of isogenic vpt3-2 and vpt4-2 strains demon-
strated a striking mislocalization of CPY to the cell surface in
both of these mutants. In each case, the predominant form of
CPY recovered from the W fraction was p2. Reduced
amounts ofmCPY and the pl form were observed also. Note
that the spheroplast fractions derived from the vpt3-2 and
vpt4-2 mutants were substantially devoid of radiolabeled
CPY antigen. Rather, both the accumulated p2 species and
the normally vacuolar mCPY were recovered from the
periplasmic and medium fractions in an essentially quantita-
tive manner. Secretion of CPY to the culture supernatant
exhibited rapid kinetics (not shown). These mislocalized
CPY species exhibited roughly equivalent distributions be-
tween the two extracellular fractions obtained from either
mutant. The secreted CPY retained its native glycosylation
pattern and did not appear to take on the heterogeneous
character observed for normally secreted glycoproteins as a
result of outer chain oligosaccharide addition (1). Similar
patterns were observed for representative mutants in the
other vpt complementation groups (data not shown). We
believe the secreted mCPY is the authentic vacuolar form of
the enzyme since the vpt strains exhibited low levels ofCPY
activity at the cell surface whereas the VPT+ strains did not.
To test whether cellular functions normally required for
protein traffic from the Golgi complex to the cell surface were
similarly required for the transit of CPY to the cell surface in
vpt mutants, the secl-J allele (2) was crossed into a vpt3-1
strain. The vpt3-1 secl-1ts double mutant did not secrete CPY
at the restrictive growth temperature (370C) but efficiently
secreted CPY at the permissive temperature (not shown).
DISCUSSION
We have employed the SUC2 gene fusion approach as an
initial strategy to genetically analyze the mechanism em-
ployed by yeast to properly deliver CPY to the vacuole. Gene
fusion technology has been successfully applied in both
prokaryotic and eukaryotic systems for purposes of mapping
specific localization determinants within proteins and for
devising genetic schemes for the identification of cellular
components involved in particular localization processes (12,
28-30). The data reported here indicate that the vacuolar
targeting problem should also be amenable to analysis using
gene fusions.
We have demonstrated that the amino-terminal 433 resi-
dues of CPY are sufficient to redirect invertase, a normally
secreted enzyme, to the yeast vacuole. It would seem,
therefore, that the vacuolar targeting determinant that is
elaborated by CPY must reside within this rather large
VPT








FIG. 3. Fractionation ofCPY in VPT+ and mutant vpt yeast. Cells were radiolabeled for 30 min with 35SOt- in medium that contained bovine
serum albumin at 1 mg/ml. Incorporation of label was terminated by the addition of NaN3 (10 mM). Cells were converted to whole culture (W),
spheroplast (S), periplasmic (P), and culture medium (M) fractions. Radiolabeled CPY was precipitated from each and analyzed by
NaDodSO4/PAGE and autoradiography. The amount of each cell fraction analyzed is representative of equal numbers of labeled cells.
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amino-terminal segment of the protein. The CPY targeting
determinant(s) must therefore exhibit a functional dominance
over any secretory information that may be present in mature
invertase. We have recently obtained evidence that as few as
50 amino-terminal CPY residues are sufficient to divert
invertase to the vacuole (unpublished data). We believe that
CPY-Inv433 delivery to the vacuole provides an accurate
representation of the route that is taken by wild-type CPY to
this organelle. Other than the observation that both CPY and
CPY-Inv433 are targeted to the vacuole, there are two
reasons for concluding that this is so. First, CPY-Inv433
exhibited the same overproduction-related mislocalization
phenotype that has been observed for wild-type CPY (24).
Second, unlinked mutations that resulted in mislocalization
of vacuolar CPY-Inv433 to the cell surface resulted in a
similar, fusion-independent, mislocalization of wild-type
CPY.
The vpt mutants exhibit major defects in the proper
localization of CPY. As such, these mutants appear to be
altered in cellular components that play an important role in
mediating protein traffic to the yeast vacuole. Our initial
results indicate that vacuolar protein traffic is a complex
process that requires the participation of at least eight gene
products. Rothman and Stevens (31) have employed a dif-
ferent approach to isolate vacuolar protein localization mu-
tants that behave similarly to those we have described here.
Preliminary comparisons of the two sets of mutants suggest
that at least 14 complementation groups have been defined
(unpublished results). The large number of complementation
groups uncovered in these mutant analyses suggests that
there may be several points in the vacuole delivery pathway
where targeting can be blocked, with ensuing mislocalization
to the cell surface, and that many gene products are involved.
Indeed, it remains to be determined whether the vpt mutants
are defective in protein sorting events (possibly at the level
of the Golgi complex) or if they are affected in postsorting
delivery events (e.g., vesicular traffic to the vacuole). Sig-
nificantly, secreted CPY did not take on the hyperglycosyl-
ated form of normally secreted glycoproteins (Fig. 3). Our
results do not rule out the possibility that the mislocalized
CPY is secreted via a route alternative to that taken by other
secretory glycoproteins such as invertase. However, the
dependence of CPY secretion in a vpt3-1 strain on SECI
function suggests that normal secretion and vpt-mediated
secretion of CPY share at least one component of the late
portion of the yeast secretory pathway. Secretion of wild-
type invertase as well as bulk media and periplasmic
polypeptides appear to be unaltered in vpt strains. It also
seems that the vpt mutants may be pleiotropically defective
in vacuolar protein biogenesis, as a PEP4-SUC2 fusion
protein was secreted in these mutants, and we have observed
that proteinase B activity is depressed in these mutants, an
expected consequence of proteinase B mislocalization (D.
Klionsky and S.D.E., unpublished results). Furthermore, we
have observed the appearance of several polypeptide species
in bulk periplasmic and media fractions of vpt mutants that
were not observed in fractions derived from the isogenic VPT
parent.
An interesting feature of the vpt mutants reported here is
that many of these strains show no significant growth defects
or conditional phenotypes. Indeed, some vpt strains exhibit
quite normal vacuoles on the basis of morphology and
fractionation properties. Thus, even though CPY, and per-
haps several other vacuolar components, is secreted in vpt
strains, these mutants are still capable of assembling a
vacuole. There may exist several pathways for vacuolar
protein traffic in yeast and we have perturbed only one of
provided us with an initial genetic handle on how the cell
delivers proteins to the yeast vacuole. We hope that through
continued genetic analyses of vacuole assembly, coupled
with a more detailed biochemical understanding of the many
VPT gene products, we will ultimately be able to develop a
molecular appreciation of the mechanisms by which intra-
cellular protein traffic to the yeast vacuole is regulated.
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